Seek Returns

GILD vs. MTD: Gilead Sciences vs. Mettler-Toledo Stock Comparison

How do Gilead Sciences (GILD) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Gilead Sciences (GILD) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while MTD is classified in Life Sciences Tools & Services.

Company profile comparison for Gilead Sciences (GILD) and Mettler-Toledo (MTD)
Profile ItemGILDMTD
NameGilead Sciences Inc.Mettler-Toledo International Inc.
Country/RegionUnited StatesSwitzerland
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization207.00 billion USD34.25 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJanuary 22, 1992November 14, 1997
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

GILD
MTD
GSPC
Loading price history…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Gilead Sciences (GILD) and Mettler-Toledo (MTD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Gilead Sciences (GILD) and Mettler-Toledo (MTD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Gilead Sciences (GILD) and Mettler-Toledo (MTD)
MetricGILDMTD
Total Return (1Y)45.69%21.58%
Total Return (3Y, Annualized)35.30%19.54%
Total Return (5Y, Annualized)25.00%2.36%

Risk Profile

Drawdown History

GILD
MTD
GSPC
Loading price history…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Gilead Sciences (GILD) and Mettler-Toledo (MTD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Gilead Sciences (GILD) and Mettler-Toledo (MTD)
MetricGILDMTD
Volatility (1Y, Annualized)27.57%31.70%
Beta (5Y)0.361.15
Max Drawdown (5Y)-26.59%-43.47%
Avg. Volume (3M)5.98M197.80K

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
GILD and MTD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Gilead Sciences (GILD) and Mettler-Toledo (MTD)
MetricGILDMTD
Sharpe Ratio (1Y)1.500.55
Sortino Ratio (1Y)2.480.75

Profitability

ROE (TTM)

Mettler-Toledo (MTD) has no ROE value reported for this period; Gilead Sciences (GILD) reports a negative figure of -22.45%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
MTD
--
Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): MTD does not report ROE, so it has no value marker; GILD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Mettler-Toledo (MTD) reports 22.25%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD
22.25%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Gilead Sciences (GILD) at 42.43% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max
83.12%
MTD
28.70%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Gilead Sciences (GILD) and Mettler-Toledo (MTD)
MetricGILDMTD
ROE (TTM)-22.45%--
ROA (TTM)13.47%20.09%
Net Margin (TTM)-12.46%22.25%
Operating Margin (TTM)42.43%28.70%
Gross Margin (TTM)79.95%59.16%

Growth

Revenue Growth

Both Gilead Sciences (GILD) at 2.39% and Mettler-Toledo (MTD) at 3.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than Mettler-Toledo (MTD) at 3.88%, which is closer to a typical peer reading.

Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Gilead Sciences (GILD) and Mettler-Toledo (MTD)
MetricGILDMTD
Revenue Growth (YoY)2.39%3.98%
Revenue Growth (3Y CAGR)2.57%0.90%
EPS Growth (YoY)1,684.21%3.88%
EPS Growth (3Y CAGR)23.04%3.06%

Financial Strength

Current Ratio (MRQ)

Both Gilead Sciences (GILD) at 1.38 and Mettler-Toledo (MTD) at 1.10 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
MTD
1.10
Min
0.10
Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Debt sits unusually high against shareholders’ equity for both Gilead Sciences (GILD) at 2.02 and Mettler-Toledo (MTD) at 26.06 — each debt-to-equity ratio is above its industry benchmark range.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD
26.06
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Gilead Sciences (GILD) and Mettler-Toledo (MTD)
MetricGILDMTD
Current Ratio (MRQ)1.381.10
Debt / Equity (MRQ)2.0226.06
Net Debt / EBITDA1.251.58

Dividends

Dividend Yield (TTM)

Mettler-Toledo (MTD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Mettler-Toledo (MTD) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Gilead Sciences (GILD) and Mettler-Toledo (MTD)
MetricGILDMTD
Dividend Yield (TTM)1.94%0.00%
Dividend Payout Ratio (TTM)43.46%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Mettler-Toledo (MTD) trades at 37.38 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max
85.34
Q3
43.46
MTD
37.38
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): GILD does not report P/E ratio, so it has no value marker; MTD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max
58.18
Q3
25.77
MTD
8.16
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Measured against book value, both Gilead Sciences (GILD) at 15.88 and Mettler-Toledo (MTD) at 442.71 look expensive — each P/B ratio sits above its industry’s benchmark range.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD
442.71
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Gilead Sciences (GILD) vs. Mettler-Toledo (MTD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Gilead Sciences (GILD) and Mettler-Toledo (MTD)
MetricGILDMTD
P/E Ratio (TTM)--37.38
P/S Ratio (TTM)6.688.16
P/B Ratio (MRQ)15.88442.71
Free Cash Flow Yield (TTM)5.16%1.97%